BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Announces Publication of a Compassionate Use Case Study of a Critical COVID-19 Patient
August 27, 2021 12:46 ET | BioAegis Therapeutics
Gelsolin immunomodulator treatment associated with patient’s rapid recovery. NORTH BRUNSWICK, N.J., Aug. 27, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection
June 29, 2021 13:58 ET | BioAegis Therapeutics
NORTH BRUNSWICK, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
Logo (3).png
Cancer Immunotherapy Market Worth $152.83 Billion by 2024 - Exclusive Report by Meticulous Research®
October 30, 2018 09:18 ET | Meticulous Market Research Pvt. Ltd.
LONDON, Oct. 30, 2018 (GLOBE NEWSWIRE) -- According to the latest publication from Meticulous Research®, the global cancer immunotherapy market is expected to grow at a CAGR of 13.8% from 2018 to...
Qu Biologics Enrolls First Two Participants in Phase 2a Clinical Trial for Lung Cancer
February 04, 2015 10:05 ET | Qu Biologics;BC Cancer Agency
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 4, 2015) - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body's...